The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, said Thursday that he has Parkinson’s disease.

Conductor Daniel Barenboim says he has been diagnosed with Parkinson’s disease. The 82-year-old issued a statement Thursday on Instagram. He has appeared more frail since 2022, canceling scheduled performances that included a new production of Wagner’s Ring Cycle in Berlin.